Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Grey Wolf Therapeutics
OncoNano Medicine, Inc.
University of Pittsburgh
Regeneron Pharmaceuticals
Rakuten Medical, Inc.
Vyriad, Inc.
Regeneron Pharmaceuticals
ISA Pharmaceuticals
ISA Pharmaceuticals
OncoResponse, Inc.
University of Miami